Theranostics infrastructure

From site activation
to first patient,
in half the time.

nuq.ai gives pharma companies and healthcare teams a clear path to stand up and run efficient theranostics programs — replacing paper checklists, fragmented ordering portals, and tribal knowledge with one coordinated platform.

Talk to us
nuq.ai — Novartis Western US Network
Sites treating
7
of 12 activated
In setup
4
Avg 58% ready
Blockers
9
3 critical
SiteReadinessStageStatus
Pacific Medical Center
100%		CompleteTreating
Bay Valley Health
100%		CompleteTreating
Summit Health — San Jose
58%		Stage 4In setup
Coastal Medical Group
42%		Stage 3In setup
Desert Health — Phoenix
10%		Stage 1Blocked
The problem

Pharma companies are losing months of revenue waiting for hospital sites to get ready, while hospitals are losing patients because nobody has given them a clear path to set up and run an efficient theranostics program.

$23B
Novartis US RLT infrastructure investment through 2030
200+
New theranostics sites needed in the US in the next 3 years
47 days
Average delay from site qualification to first patient — today
$50k+
Typical revenue missed per unbilled treatment — undetected without nuq.ai
Two ways in

Deploy through pharma.
Or buy it directly.

nuq.ai works for health systems of any size — whether you come through a pharma partnership or purchase access on your own.

Path 1
Deployed by pharma
Pharma activates sites. Sites use it free.
›

Novartis, Lilly, or Bristol Myers Squibb deploys nuq.ai to every site they activate. Sites get access as part of their therapy program. Pharma pays — sites use it free.

Includes
Full platform — all 4 roles
Executive network dashboard
Multi-site management
Site activation tracking
Protections
Data owned by hospital, not pharma
Program continues if pharma relationship changes
Patient data never visible to pharma
Regulatory records stored permanently
Talk to us about pharma deployment
Path 2
Direct subscription
Hospitals and clinics buy direct. No pharma needed.
›
How it works

One platform. Two users.
One distribution model.

Pharma companies deploy nuq.ai to every site they activate. Sites use it free. Everyone wins.

◈
Pharma pays, sites use free
Novartis, Lilly, Bristol Myers Squibb deploy nuq.ai as their site activation tool. Every new site gets access automatically — no hospital procurement cycle required.
◎
Site readiness in 6 stages
Guided setup from NRC licensing through first patient. Each stage has a specific checklist, owner, and deadline — no more tribal knowledge or paper binders.
⊕
Coordinator's day, automated
Patient tracking, dose ordering across ROME, Cardinal, Sophie and RLS, insurance reauthorization, and regulatory compliance — all in one place. Your team stops juggling 8 disconnected systems.
↗
Revenue recovery, built in
nuq.ai cross-references dose administration records against billing. If a $52,000 treatment was never billed, you find out before the window closes — not a year later.
Patients
Doses
Regulatory
Today's tasks
3
overdue
Active patients
4
in cycles
Doses today
2
confirmed
Credits pending
1
$42k
Today's tasks
RJ — Order labs CBC, CMP, PSA
Overdue
ML — 3-day follow-up call
Today
AC — Insurance reauth follow-up
Today
TW — Order Pluvicto via ROME
Jun 11
Site setup
✓
License & credentialing
100%
✓
Infrastructure
100%
✓
Staff training
100%
4
Workflow & docs
60%
5
Referral pathway
15%
Who it's for

Four roles. One product.
Strict data separation.

Each user sees only what they need. Patient data never reaches pharma. Financial data never reaches clinical teams.

01
◈
Executive
Novartis / Lilly / Bristol Myers Squibb Medical Affairs
Network-level visibility across all sites. Revenue impact, blockers, activation velocity.
Site readiness across entire network
Revenue at risk from delayed activations
Critical blockers requiring escalation
02
◎
Site Activation
Site Activation Manager · Pharma field team
Guided 6-stage activation checklist. Used by pharma field teams to qualify and stand up new treatment sites — tracking licensing, infrastructure, training, and referral pathways.
6-stage readiness checklist with owners
Cross-department coordination tracker
Multi-site switching for regional directors
03
⊕
Nuc med team
Coordinator · Technologist · Radiologist
Day-to-day clinical operations. Patient tracking, dose ordering, regulatory compliance — unified across all radiopharmaceutical ordering portals.
Unified today's task view across all patients
Automated dose ordering agent
One-click credit requests on canceled doses
04
↗
Hospital exec
Imaging / Nuclear Medicine Director
Program-level numbers without clinical detail. Patients treated, revenue, completion rates, and unbilled treatment alerts.
Patients treated by therapy type
Revenue recovery — unbilled treatment detection
Referral-to-treatment conversion tracking
Market timing

The infrastructure is being built.
The software isn't.

Pharma has committed billions to RLT manufacturing. The clinical site network to absorb it doesn't exist at scale yet. That gap is the market.

$23B
Novartis US infrastructure investment through 2030, with 5 dedicated RLT manufacturing facilities planned or under construction.
$30.7B
Projected global nuclear medicine market by 2034, up from $7.8B today — a 4x expansion requiring a proportional increase in clinical sites.
25%
Projected shortfall in licensed nuclear medicine technologists over the next 5 years — making workflow efficiency not optional, but essential.
Who we're talking to
Novartis — Pluvicto & Lutathera
200+ certified US sites. 130+ more planned. Each activation is manual today.
Eli Lilly — Point Biopharma pipeline
$4.5B RLT investment. Building US site network from scratch.
Bristol Myers Squibb — RayzeBio
$4.1B acquisition. No existing RLT site infrastructure. Starting from zero.
Lantheus Holdings
Leading radiopharmaceutical company across diagnostics and therapy. PYLARIFY and growing RLT pipeline.
Built by people who lived it
15 years running nuclear medicine programs. We know what Coordinator needs because one of us was her supervisor.
What the industry is saying

The problem is well-known.
The solution isn't.

"As molecular imaging continues to scale, success will depend on more than individual products — it requires building the ecosystem around them."

Eric Ruedinger — VP & GM, Pharmaceutical Diagnostics, GE HealthCare · SNMMI 2026

"Ensuring health care systems are ready for RLTs through optimizing treatment centers, investing in infrastructure and personnel, and appropriate regulatory frameworks."

Novartis — RLT Strategic Commitment, 2025

"There's not a software that does it all. We're just piecing all of this together — paper checklists, eight different ordering portals, tribal knowledge."

Site Director — Nuclear Medicine Supervisor, 15 years · co-founder, nuq.ai
Early access

If you're activating theranostics sites, we should talk.

We're working with a small number of pharma medical affairs and commercial teams to pilot nuq.ai. If you're at Novartis, Lilly, Bristol Myers Squibb, AstraZeneca or Cardinal Health — reach out.

We'll respond within 48 hours. No spam, ever.